ClinicalTrials.gg
CompletedNCT07686627HEALUpdated Oct 20, 2026

ShotBlocker and Warm Gel Pack During Neonatal Heel Prick (HEAL)

An interventional study of ShotBlocker and Warm Gel Pack in Procedural Pain, Heel Prick and Newborn, sponsored by Marmara University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 0 Days to 1 Month, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Marmara University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Oct 2024, registered Jun 2026).
Updated Oct 20, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
0 Days to 1 Month
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Pain, Procedural with a site in Turkey — 14 open to participants now, 14 under way, none of them phase 3. Pain, Procedural · Turkey.

Enrollment
20th of 79
139 · median 100
Started
2024
with 11 others
No phase
77 of 81
13 open now
Registered
60th of 81
by date
Lead sponsor
4 of 81
Marmara University

Among the 81 studies in Pain, Procedural with a site in Turkey, this one is the 20th largest by enrollment of the 79 interventional ones that give a count, is one of 12 that started in 2024, is one of 77 with no phase, and was the 60th registered.

Pain, Procedural

246 studies on the registry are indexed under Pain, Procedural; 66 are open to participants now.

Browse Pain, Procedural studies →

Open to participants now

14 of the 81 studies in Pain, Procedural with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 30 Pain, Procedural studies recruiting now, 13 (43%) set no upper age limit and 15 (50%) stop at 75 or younger; 14 take children under 18; 6 take healthy volunteers.

This study: 0 Days to 1 Month · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Pain, Procedural with a site in Turkey, or all of them as a file.
02

Study summary

This study evaluated the effects of ShotBlocker and a warm gel pack on pain, comfort, and physiological parameters during heel prick testing in healthy term newborns. A three-arm randomized controlled trial was conducted at a city hospital between October 2024 and October 2025. Newborns were randomly assigned to the ShotBlocker group, warm gel pack group, or routine care group. Pain was assessed using the Neonatal Infant Pain Scale (NIPS), and comfort was assessed using the COMFORTneo. Heart rate, respiratory rate, oxygen saturation, and heel temperature were also measured before and after the procedure. The study aimed to compare the effectiveness of these non-pharmacological interventions during routine heel prick testing.

03

Conditions studied

  • Procedural Pain
  • Heel Prick
  • Newborn

Browse trials for

Keywords

  • Newborn
  • Heel Prick
  • Procedural Pain
  • ShotBlocker
  • Warm Gel Pack
  • Pain Management
  • Neonatal Pain
  • Nonpharmacological Intervention
  • NIPS
  • NCBS
  • COMFORTneo
04

Who can participate

Ages eligible
0 Days to 1 Month
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age ≥38 weeks
  • Healthy newborn
  • Scheduled for routine heel prick testing as part of the newborn screening program
  • 1-minute APGAR score ≥7
  • No acute illness causing pain
  • No invasive procedures other than vaccination after birth

Exclusion criteria

Exclusion Criteria:

  • Mother does not speak Turkish
  • Parent unwilling to participate
  • Multiple pregnancy
  • Maternal or fetal complications during delivery
  • Known or suspected genetic or metabolic disorder in the mother or infant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    ShotBlocker

    Participants received the ShotBlocker device during routine heel prick testing. The device was placed at the heel puncture site immediately before the procedure.

    Device: ShotBlocker

  • Experimental
    Warm Gel Pack

    Participants received a warm gel pack before routine heel prick testing. The gel pack was applied to the heel until the target temperature of 38-40°C was reached before blood sampling.

    Device: Warm Gel Pack

  • No intervention
    Routine Care

    Participants received routine heel prick testing without ShotBlocker or warm gel pack application.

Interventions

  • DeviceShotBlocker

    The ShotBlocker device was applied at the heel puncture site during routine heel prick testing. The device was positioned immediately before the procedure and remained in place during blood collection.

  • DeviceWarm Gel Pack

    A single-use warm gel pack was applied to the heel before routine heel prick testing. The heel temperature was maintained between 38°C and 40°C before blood sampling

06

What researchers measure

Primary outcomes

  1. Neonatal Infant Pain Scale (NIPS) Score

    Pain intensity will be assessed immediately after heel prick using the Neonatal Infant Pain Scale (NIPS). The NIPS is a behavioral pain assessment tool consisting of six indicators (facial expression, crying, breathing pattern, arm movements, leg movements, and state of arousal). Total scores range from 0 to 7, with higher scores indicating greater pain intensity. Scores \>3 indicate clinically significant pain.

    Time frame: Immediately after heel prick testing

Secondary outcomes

  1. COMFORTneo

    Comfort will be assessed before and immediately after heel prick using the COMFORTneo. The NCBS consists of six behavioral items, each scored from 1 to 5, yielding a total score ranging from 6 to 30. Higher scores indicate poorer comfort (greater pain/distress), whereas lower scores indicate better comfort. Scores ≥14 indicate discomfort/distress

    Time frame: Before and immediately after heel prick testing

  2. Heart Rate

    Heart rate was measured before and immediately after heel prick testing.

    Time frame: Before and immediately after heel prick testing

  3. Respiratory Rate

    Respiratory rate was measured before and immediately after heel prick testing.

    Time frame: Before and immediately after heel prick testing

  4. Oxygen Saturation

    Oxygen saturation was measured before and immediately after heel prick testing.

    Time frame: Before and immediately after heel prick testing

  5. Heel Temperature

    Heel temperature was measured before and immediately after heel prick testing.

    Time frame: Before and immediately after heel prick testing

07

Study locations

1 site
  • Kocaeli City Hospital
    Kocaeli, İzmit 41060, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Oct 2025, 11 months.

Of 145 non-industry interventional studies with no phase under Pain, Procedural, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's 11 months is above that.

Counting every sponsor, half of 145 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Oct 2025 → Oct 2024, primary completion May 2026 → Oct 2025 and completion May 2026 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 7, 2026
StartActual
Oct 8, 2024was Oct 2025
Primary completionActual
Oct 1, 2025was May 2026
CompletionActual
Oct 1, 2025was May 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2025→Oct 8, 2024
Oct 20, 2026
Primary completion
May 1, 2026→Oct 1, 2025
Oct 20, 2026
Study completion
May 1, 2026→Oct 1, 2025
Oct 20, 2026
Enrollment
147→139
Oct 20, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Neonatal Comfort Behavior Scale (NCBS) ScoreNow COMFORTneoTime frame: Before and immediately after heel prick testing
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Oct 1, 2025→Oct 8, 2024
    Primary completion May 1, 2026→Oct 1, 2025
    Study completion May 1, 2026→Oct 1, 2025
    Enrollment 147→139
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Neonatal Comfort Behavior Scale (NCBS) ScoreNow COMFORTneoTime frame: Before and immediately after heel prick testing
    + 4 other changes: verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07686627
Lead sponsor
Marmara University
Responsible party
Ayşegül Şimşek (Associate Professor, Marmara University) — Principal investigator
First posted
Jul 7, 2026
Start date
Oct 8, 2024
Primary completion
Oct 1, 2025
Completion
Oct 1, 2025
Last update
Oct 20, 2026

Study contacts

Aysegul Simsek, PhD
principal investigator · Marmara University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion